Schweighardt B - Search Results

1

Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.

Zori R, Thomas JA, Shur N, Rizzo WB, Decker C, Rosen O, Li M, Schweighardt B, Larimore K, Longo N. Zori R, et al. Among authors: schweighardt b. Mol Genet Metab. 2018 Nov;125(3):217-227. doi: 10.1016/j.ymgme.2018.06.010. Epub 2018 Aug 23. Mol Genet Metab. 2018. PMID: 30146451 Clinical Trial.

2

Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials.

Gupta S, Lau K, Harding CO, Shepherd G, Boyer R, Atkinson JP, Knight V, Olbertz J, Larimore K, Gu Z, Li M, Rosen O, Zoog SJ, Weng HH, Schweighardt B. Gupta S, et al. Among authors: schweighardt b. EBioMedicine. 2018 Nov;37:366-373. doi: 10.1016/j.ebiom.2018.10.038. Epub 2018 Oct 23. EBioMedicine. 2018. PMID: 30366815 Free PMC article. Clinical Trial.

3

Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria.

Qi Y, Patel G, Henshaw J, Gupta S, Olbertz J, Larimore K, Harding CO, Merilainen M, Zori R, Longo N, Burton BK, Li M, Gu Z, Zoog SJ, Weng HH, Schweighardt B. Qi Y, et al. Among authors: schweighardt b. Clin Transl Sci. 2021 Sep;14(5):1894-1905. doi: 10.1111/cts.13043. Epub 2021 May 31. Clin Transl Sci. 2021. PMID: 34057292 Free PMC article. Clinical Trial.

4

Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.

Long B, Tompkins T, Decker C, Jesaitis L, Khan S, Slasor P, Harmatz P, O'Neill CA, Schweighardt B. Long B, et al. Among authors: schweighardt b. Clin Ther. 2017 Jan;39(1):118-129.e3. doi: 10.1016/j.clinthera.2016.11.017. Epub 2016 Dec 10. Clin Ther. 2017. PMID: 27955919 Free article. Clinical Trial.

5

Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome.

Melton AC, Soon RK Jr, Tompkins T, Long B, Schweighardt B, Qi Y, Vitelli C, Bagri A, Decker C, O'Neill CA, Zoog SJ, Jesaitis L. Melton AC, et al. Among authors: schweighardt b. J Immunol Methods. 2017 Jan;440:41-51. doi: 10.1016/j.jim.2016.10.006. Epub 2016 Oct 24. J Immunol Methods. 2017. PMID: 27789297 Free article. Clinical Trial.

6

Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.

Long BR, Veron P, Kuranda K, Hardet R, Mitchell N, Hayes GM, Wong WY, Lau K, Li M, Hock MB, Zoog SJ, Vettermann C, Mingozzi F, Schweighardt B. Long BR, et al. Among authors: schweighardt b. Mol Ther. 2021 Feb 3;29(2):597-610. doi: 10.1016/j.ymthe.2020.12.008. Epub 2020 Dec 10. Mol Ther. 2021. PMID: 33309883 Free PMC article.

7

Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.

Schweighardt B, Tompkins T, Lau K, Jesaitis L, Qi Y, Musson DG, Farmer P, Haller C, Shaywitz AJ, Yang K, O'Neill CA. Schweighardt B, et al. Clin Ther. 2015 May 1;37(5):1012-1021.e6. doi: 10.1016/j.clinthera.2014.11.005. Epub 2014 Dec 6. Clin Ther. 2015. PMID: 25487082 Clinical Trial.

8

Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome.

Qi Y, Musson DG, Schweighardt B, Tompkins T, Jesaitis L, Shaywitz AJ, Yang K, O'Neill CA. Qi Y, et al. Among authors: schweighardt b. Clin Pharmacokinet. 2014 Dec;53(12):1137-47. doi: 10.1007/s40262-014-0173-y. Clin Pharmacokinet. 2014. PMID: 25234648 Free PMC article. Clinical Trial.

9

Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study.

Cherukuri A, Cahan H, de Hart G, Van Tuyl A, Slasor P, Bray L, Henshaw J, Ajayi T, Jacoby D, O'Neill CA, Schweighardt B. Cherukuri A, et al. Among authors: schweighardt b. Clin Immunol. 2018 Dec;197:68-76. doi: 10.1016/j.clim.2018.09.003. Epub 2018 Sep 8. Clin Immunol. 2018. PMID: 30205177 Clinical Trial.

10

The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy.

Long BR, Sandza K, Holcomb J, Crockett L, Hayes GM, Arens J, Fonck C, Tsuruda LS, Schweighardt B, O'Neill CA, Zoog S, Vettermann C. Long BR, et al. Among authors: schweighardt b. Mol Ther Methods Clin Dev. 2019 Apr 11;13:440-452. doi: 10.1016/j.omtm.2019.03.006. eCollection 2019 Jun 14. Mol Ther Methods Clin Dev. 2019. PMID: 31193016 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters